En pacientes con diabetes tipo 2, las concentraciones medias en estado estacionario tras la administracin subcutnea de 0.5 mg y 1 mg de semaglutida fueron de aproximadamente 16 nmol/l y 30 nmol/l, respectivamente
Study Findings The studys random-effects model revealed that once-weekly subcutaneous semaglutide and once-daily subcutaneous liraglutide were both significantly associated with greater weight reductions than the control arms
Watch-outs to know: Some experts have concerns that TA-1 could aggravate an autoimmune disorder, and while the reported side effects in clinical settings are mild, health experts are wary about the unofficial use of TA-1
The drugs, also commonly known as glucagon-like peptide 1 (GLP-1) receptor agonists or GLP-1 analogues, are normally prescribed for patients who have not been able to control their condition with tablet medication
Certain side effects have been reported in clinical trials, including gastrointestinal discomfort and allergic reactions